Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors
- 18 September 2015
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 87 (1) , 112-120
Abstract
Most nucleoside kinases, besides the catalytic domain, feature an allosteric domain which modulates their activity. Generally, non-substrate analogs, interacting with allosteric sites, represent a major opportunity for developing more selective and safer therapeutics. We recently developed a series of non-nucleoside non-competitive inhibitors of human adenosine kinase (hAK), based on a pyrrolobenzoxa(thia)zepinone scaffold. Based on computational analysis, we hypothesized the existence of a novel allosteric site on hAK, topographically distinct from the catalytic site. In this study, we have adopted a multidisciplinary approach including molecular modeling, biochemical studies, and site-directed mutagenesis to validate our hypothesis. Based on a three-dimensional model of interaction between hAK and our molecules, we designed, cloned, and expressed specific, single and double point mutants of hAK (Q74A, Q78A, H107A, K341A, F338A, and Q74A-F338A). Kinetic characterization of recombinant enzymes indicated that these mutations did not affect enzyme functioning; conversely, mutated enzymes are endowed of reduced susceptibility to our non-nucleoside inhibitors, while maintaining comparable affinity for nucleoside inhibitors to the wild-type enzyme. This study represents the first characterization and validation of a novel allosteric site in hAK and may pave the way to the development of novel selective and potent non-nucleoside inhibitors of hAK endowed with therapeutic potential.Keywords
Funding Information
- Consiglio Nazionale delle Ricerche
- dell'Università e della Ricerca ‘Progetto d'interesse invecchiamento’
- FIRB (RBAU01LSR4_001)
- Regione Lombardia (13810040)
This publication has 25 references indexed in Scilit:
- Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesisJournal of Clinical Investigation, 2013
- Adenosine Kinase: Exploitation for Therapeutic GainPharmacological Reviews, 2013
- Reversible RNA adenosine methylation in biological regulationTrends in Genetics, 2013
- Adenosine Metabolism, Adenosine Kinase, and Evolution2012
- Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replicationProceedings of the National Academy of Sciences, 2012
- Adenosine kinase regulation of cardiomyocyte hypertrophyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Downregulation of Hippocampal Adenosine Kinase after Focal Ischemia as Potential Endogenous Neuroprotective MechanismJournal of Cerebral Blood Flow & Metabolism, 2007
- Transgenic Overexpression of Adenosine Kinase Aggravates Cell Death in IschemiaJournal of Cerebral Blood Flow & Metabolism, 2007
- Neonatal hepatic steatosis by disruption of the adenosine kinase geneProceedings of the National Academy of Sciences, 2002
- Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cellsCell, 1977